Cargando…

Insulin doses requirements in patients with type 1 diabetes using glargine U300 or degludec in routine clinical practice

There are not many real-world studies evaluating daily insulin doses requirements (DIDR) in patients with type 1 diabetes (T1D) using second-generation basal insulin analogs, and such comparison is necessary. The aim of this study was to compare DIDR in individuals with T1D using glargine 300 UI/mL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carral San Laureano, Florentino, Tomé Fernández-Ladreda, Mariana, Jiménez Millán, Ana Isabel, García Calzado, Concepción, Ayala Ortega, María del Carmen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8223633/ https://www.ncbi.nlm.nih.gov/pubmed/33771843 http://dx.doi.org/10.1136/jim-2020-001633

Ejemplares similares

Insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?
por: Buscemi, Silvio, et al.
Publicado: (2019)

Response to insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?
por: Yamabe, Mizuho
Publicado: (2019)

Day‐to‐day variability of porcine lente, insulin glargine 300 U/mL and insulin degludec in diabetic dogs
por: Miller, Michelle, et al.
Publicado: (2021)

Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec
por: Kawaguchi, Yuji, et al.
Publicado: (2019)

Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial
por: Evans, Marc, et al.
Publicado: (2020)

A comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin‐naïve patients with type 2 diabetes
por: Tibaldi, Joseph, et al.
Publicado: (2019)

In Silico Head-to-Head Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL in Type 1 Diabetes
por: Schiavon, Michele, et al.
Publicado: (2020)

Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial
por: Bolli, Geremia B., et al.
Publicado: (2021)

Comparison of insulin glargine 300 U/mL and insulin degludec using flash glucose monitoring: A randomized cross‐over study
por: Yamabe, Mizuho, et al.
Publicado: (2018)

Comment on “a comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin‐naïve patients with type 2 diabetes”
por: Freemantle, Nick, et al.
Publicado: (2019)

Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial
por: Philis-Tsimikas, Athena, et al.
Publicado: (2020)

Comparison of the efficacy and safety of insulin degludec/aspart (twice‐daily injections), insulin glargine 300 U/mL, and insulin glulisine (basal–bolus therapy)
por: Kawaguchi, Yuji, et al.
Publicado: (2019)

Insulin degludec: Lower day‐to‐day and within‐day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes
por: Heise, Tim, et al.
Publicado: (2017)

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
por: Steinstraesser, A, et al.
Publicado: (2014)

Glargine and degludec: Solution behaviour of higher dose synthetic insulins
por: Adams, Gary G., et al.
Publicado: (2017)

Comparative Effectiveness of Switching From First-Generation Basal Insulin to Glargine 300 U/ml or Degludec 100 U/ml in Type 1 Diabetes: The RESTORE-1 Study
por: Laviola, Luigi, et al.
Publicado: (2020)

Effectiveness and Safety of Insulin Glargine 300 U/ml in Comparison with Insulin Degludec 100 U/ml Evaluated with Continuous Glucose Monitoring in Adults with Type 1 Diabetes and Suboptimal Glycemic Control in Routine Clinical Practice: The OneCARE Study
por: Conget, Ignacio, et al.
Publicado: (2021)

Impact of kidney function on the safety and efficacy of insulin degludec versus insulin glargine U300 in people with type 2 diabetes: A post hoc analysis of the CONCLUDE trial
por: Pieber, Thomas R., et al.
Publicado: (2021)

Comparison of the Impact of Insulin Degludec U100 and Insulin Glargine U300 on Glycemic Variability and Oxidative Stress in Insulin-Naive Patients With Type 2 Diabetes Mellitus: Pilot Study for a Randomized Trial
por: Vrebalov Cindro, Pavle, et al.
Publicado: (2022)

rDNA insulin glargine U300 – a critical appraisal
por: Wang, Fei, et al.
Publicado: (2016)

Commentary to “Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec” by Kawaguchi et al. Diabetes Therapy 2019
por: Pieber, Thomas R., et al.
Publicado: (2020)

Duration of type 2 diabetes does not appear to moderate hypoglycaemia rate with insulin degludec versus insulin glargine U100
por: Alexopoulos, Anastasia‐Stefania, et al.
Publicado: (2021)

Comparative clinical outcomes of insulin degludec and insulin glargine 300 U/mL after switching from other basal insulins in real‐world patients with type 1 and type 2 diabetes
por: Oya, Junko, et al.
Publicado: (2021)

Nocturnal Glycemic Control with New Insulin Glargine 300 U/mL
por: Yu, Neng Chun
Publicado: (2019)

Insulin depot absorption modeling and pharmacokinetic simulation with insulin glargine 300 U/mL
por: Lindauer, Klaus, et al.
Publicado: (2019)

Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U100 in Patients with Type 1 and Type 2 Diabetes Mellitus in Serbia
por: Lalić, Nebojša, et al.
Publicado: (2018)

Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria
por: Russel-Szymczyk, Monika, et al.
Publicado: (2019)

Improved health status with insulin degludec compared with insulin glargine in people with Type 1 diabetes
por: Home, P D, et al.
Publicado: (2012)

Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting
por: Evans, Marc, et al.
Publicado: (2018)

Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function
por: Hartmann, Thorsten, et al.
Publicado: (2016)

Effects of Switching from Insulin Glargine or Detemir to Insulin Degludec in Patients with Type 1 Diabetes Mellitus
por: Kusunoki, Yoshiki, et al.
Publicado: (2013)

Insulin degludec does not increase antibody formation versus insulin glargine: an evaluation of phase IIIa trials
por: Vora, J., et al.
Publicado: (2016)

Effects of Insulin Degludec and Insulin Glargine U300 on Day-to-Day Fasting Plasma Glucose Variability in Individuals with Type 1 Diabetes: A Multicenter, Randomized, Crossover Study (Kobe Best Basal Insulin Study 2)
por: Miura, Hiroshi, et al.
Publicado: (2018)

Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial
por: Haluzík, Martin, et al.
Publicado: (2020)

Low Blood Glucose Index and Hypoglycaemia Risk: Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Type 2 Diabetes
por: Kovatchev, Boris, et al.
Publicado: (2020)

Efficacy and safety of insulin glargine 300 U/mL vs insulin degludec in patients with type 2 diabetes: A randomized, open‐label, cross‐over study using continuous glucose monitoring profiles
por: Kawaguchi, Yuji, et al.
Publicado: (2018)

Effect of Insulin Degludec Versus Insulin Glargine U100 on Hypoglycemia in Hispanic Patients With Type 2 Diabetes: Results From the SWITCH 2 Trial
por: Chaykin, Louis, et al.
Publicado: (2019)

Low within- and between-day variability in exposure to new insulin glargine 300 U/ml
por: Becker, R H A, et al.
Publicado: (2015)

Insulin glargine 300 U/mL in the management of diabetes: clinical utility and patient perspectives
por: de Galan, Bastiaan E
Publicado: (2016)

Insulin Glargine 300 U/mL Therapy in Children and Adolescents with Type 1 Diabetes
por: Maffeis, Claudio, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7kkpo79s32e1g02g9u4dbe1ss2